CLDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the investor's beginner level, long-term investment preference, and available capital, Celldex Therapeutics Inc (CLDX) is not a strong buy at this moment. The technical indicators are mixed, options data shows neutral sentiment, and the company's financial performance is weak. While there are positive catalysts in the form of analyst upgrades and upcoming trial data, the lack of immediate trading signals and the company's recent financial struggles suggest holding off on investment for now.
The MACD is below 0 and negatively expanding, indicating bearish momentum. RSI is neutral at 50.655, showing no clear trend. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below its pivot point of 33.813, with key support at 32.352 and resistance at 35.274.
Analysts have upgraded the stock with higher price targets, citing faster-than-expected trial enrollments and upcoming data readouts for barzolvolimab and other programs. The stock is entering a catalyst-rich period in 2026.
The company's financial performance in Q4 2025 showed a significant revenue drop (-89.70% YoY) and negative net income, despite some improvement in EPS and net loss reduction. The options data and technical indicators do not show strong bullish sentiment.
In Q4 2025, revenue dropped significantly by -89.70% YoY to $121,000. Net income improved to -$81.32M (up 72.68% YoY), and EPS increased to -1.22 (up 71.83% YoY). Gross margin remained at 100%.
Barclays upgraded the stock to Overweight with a price target of $45, citing strong demand for barzolvolimab and faster trial enrollments. Wolfe Research and Morgan Stanley also upgraded the stock with price targets of $44, while Stifel raised its target to $68. Goldman Sachs maintained a Neutral rating with a price target of $34.
